Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-467 in relapsed/refractory multiple myeloma
NCT04178902Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- May 2020
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 1, open-label trial of abbv-467 in multiple myeloma (MM) (2 arms), sponsored by AbbVie Inc. Primary endpoints: Number of Participants with Adverse Events at 24 months, Change in Vital Signs at 24 months and 8 more. Started May 2020; status: terminated.
02
Drugs
abbv-467
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04178902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04178902.